CheckMate-067: Raising the Bar for the Next Decade in Oncology.
作者信息
Weiss Sarah A, Kluger Harriet
机构信息
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
Yale University School of Medicine, New Haven, CT.
出版信息
J Clin Oncol. 2022 Jan 10;40(2):111-113. doi: 10.1200/JCO.21.02549. Epub 2021 Dec 2.
Abstract
摘要
相似文献
1
CheckMate-067: Raising the Bar for the Next Decade in Oncology.CheckMate-067研究：为肿瘤学领域未来十年树立更高标准
J Clin Oncol. 2022 Jan 10;40(2):111-113. doi: 10.1200/JCO.21.02549. Epub 2021 Dec 2.
2
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.美国临床肿瘤学会观点：通过定义具有临床意义的结果来提高临床试验标准。
J Clin Oncol. 2014 Apr 20;32(12):1277-80. doi: 10.1200/JCO.2013.53.8009. Epub 2014 Mar 17.
3
Raising the bar for breast health care in the United States.提高美国乳腺保健的标准。
Womens Health Issues. 2012 Mar;22(2):e129-33. doi: 10.1016/j.whi.2011.08.011. Epub 2011 Oct 28.
4
The Journal of Thoracic Oncology in the Next Decade.未来十年的《胸部肿瘤学杂志》。
J Thorac Oncol. 2016 Jan;11(1):8. doi: 10.1016/j.jtho.2015.10.012.
5
Integration between oncology and palliative care: a plan for the next decade?肿瘤学与姑息治疗的整合：未来十年的规划？
Tumori. 2017 May 12;103(3):e23. doi: 10.5301/tj.5000629.
6
Author's reply to: Integration between oncology and palliative care: a plan for the next decade?作者对《肿瘤学与姑息治疗的整合：未来十年计划？》的回复
Tumori. 2017 May 12;103(3):e24. doi: 10.5301/tj.5000631.
7
[Clinical research in oncology: which stakes for the next decade?].[肿瘤学临床研究：未来十年有哪些利害关系？]
Bull Cancer. 1999 Jun;86(6):526-8.
8
An urgent call to raise the bar in oncology.呼吁提高肿瘤学水平。
Br J Cancer. 2021 Nov;125(11):1477-1485. doi: 10.1038/s41416-021-01495-7. Epub 2021 Aug 16.
9
Evaluating Oncology Clinical Pathways: What Bar Are We Aiming for?评估肿瘤临床路径：我们的目标是什么标准？
JCO Oncol Pract. 2023 Sep;19(9):692-693. doi: 10.1200/OP.23.00376. Epub 2023 Aug 21.
10
Time has come to raise the bar in oncology clinical trials.提高肿瘤学临床试验的标准时机已至。
J Clin Oncol. 2014 Apr 20;32(12):1186-7. doi: 10.1200/JCO.2013.54.5277. Epub 2014 Mar 17.
引用本文的文献
1
Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma.可溶性CD27分别预测黑色素瘤对抗PD-1单药治疗的耐药性，但不能预测联合抗CTLA-4治疗的耐药性。
EMBO Mol Med. 2025 May;17(5):909-922. doi: 10.1038/s44321-025-00203-9. Epub 2025 Mar 27.
2
Exploring Motives Behind Ideal Melanoma Survivorship Care Plans With Multiple Stakeholders: A Cocreation Study.与多方利益相关者共同探讨理想黑色素瘤幸存者护理计划背后的动机：一项共创研究。
JMIR Cancer. 2025 Jan 2;11:e55746. doi: 10.2196/55746.
3
Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.黑色素瘤中的肿瘤浸润淋巴细胞：从预后评估到治疗应用
Front Immunol. 2024 Dec 6;15:1497522. doi: 10.3389/fimmu.2024.1497522. eCollection 2024.
4
Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis.免疫检查点抑制剂诱导黑色素瘤患者胰腺酶升高：发病率、管理与治疗——一项多中心分析
J Eur Acad Dermatol Venereol. 2025 Sep;39(9):1656-1665. doi: 10.1111/jdv.20384. Epub 2024 Nov 20.
5
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment.下一代免疫疗法：推进癌症治疗的临床应用
J Clin Med. 2024 Oct 30;13(21):6537. doi: 10.3390/jcm13216537.
6
Long-Term Survival in Patients With Advanced Melanoma.晚期黑色素瘤患者的长期生存。
JAMA Netw Open. 2024 Aug 1;7(8):e2426641. doi: 10.1001/jamanetworkopen.2024.26641.
7
Immunotherapy in melanoma: advances, pitfalls, and future perspectives.黑色素瘤的免疫疗法：进展、陷阱与未来展望。
Front Mol Biosci. 2024 Jun 28;11:1403021. doi: 10.3389/fmolb.2024.1403021. eCollection 2024.
8
Pain Related Quality of Life in Neurofibromatosis Type 1: A Narrative Review.神经纤维瘤病 1 型相关生存质量的疼痛问题：一项叙事性综述。
Curr Pain Headache Rep. 2024 Nov;28(11):1177-1183. doi: 10.1007/s11916-024-01283-x. Epub 2024 Jun 27.
9
From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.从决策到反思：了解辅助治疗或转移性黑色素瘤免疫治疗患者的经历和未满足的护理需求。
BMC Cancer. 2024 May 30;24(1):662. doi: 10.1186/s12885-024-12410-7.
10
Clinical and translational attributes of immune-related adverse events.免疫相关不良反应的临床和转化特征。
Nat Cancer. 2024 Apr;5(4):557-571. doi: 10.1038/s43018-024-00730-3. Epub 2024 Feb 15.
本文引用的文献
1
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With V600-Mutant Melanoma.COLUMBUS 5 年更新：依维莫司或恩考芬尼联合比尼替尼对比维莫非尼用于 V600 突变型黑色素瘤患者的随机、开放标签、III 期试验。
J Clin Oncol. 2022 Dec 20;40(36):4178-4188. doi: 10.1200/JCO.21.02659. Epub 2022 Jul 21.
2
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.纳武利尤单抗联合伊匹单抗或纳武利尤单抗对比伊匹单抗治疗晚期黑色素瘤患者的长期结局。
J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.
3
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.帕博利珠单抗联合伊匹木单抗治疗抗 PD-1/PD-L1 失败的黑色素瘤。
J Clin Oncol. 2021 Aug 20;39(24):2647-2655. doi: 10.1200/JCO.21.00079. Epub 2021 May 4.
4
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.帕博利珠单抗联合阿昔替尼与纳武利尤单抗联合伊匹木单抗作为美国晚期肾细胞癌一线治疗的成本效果分析。
JAMA Netw Open. 2020 Oct 1;3(10):e2016144. doi: 10.1001/jamanetworkopen.2020.16144.
5
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
6
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.无治疗生存：免疫检查点抑制作用的新型疗效评估指标——晚期黑色素瘤患者的汇总分析
J Clin Oncol. 2019 Dec 10;37(35):3350-3358. doi: 10.1200/JCO.19.00345. Epub 2019 Sep 9.
7
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.达拉非尼联合曲美替尼治疗转移性黑色素瘤的 5 年结果。
N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.
8
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.免疫检查点抑制剂相关致命性毒性作用：系统评价和荟萃分析。
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
9
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
10
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.因不良事件而停用纳武利尤单抗和伊匹木单抗治疗的晚期黑色素瘤患者的疗效和安全性结果：随机II期和III期试验的汇总分析
J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25.
Zotero 插件